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Abstract
Background: Hypofunction of the glutamate N-Methyl-d-aspartate (NMDA) receptor has been implicated in the
pathophysiology of schizophrenia. p250GAP is a brain-enriched NMDA receptor-interacting RhoGAP. p250GAP is involved
in spine morphology, and spine morphology has been shown to be altered in the post-mortem brains of patients with
schizophrenia. Schizotypal personality disorder has a strong familial relationship with schizophrenia. Several susceptibility
genes for schizophrenia have been related to schizotypal traits.
Methods: We first investigated the association of eight linkage disequilibrium-tagging single-nucleotide polymorphisms
(SNPs) that cover the p250GAP gene with schizophrenia in a Japanese sample of 431 schizophrenia patients and 572
controls. We then investigated the impact of the risk genetic variant in the p250GAP gene on schizotypal personality traits in
180 healthy subjects using the Schizotypal Personality Questionnaire.
Results: We found a significant difference in genotype frequency between the patients and the controls in rs2298599
(x
2=17.6, p=0.00015). The minor A/A genotype frequency of rs2298599 was higher in the patients (18%) than in the
controls (9%) (x
2=15.5, p=0.000083). Moreover, we found that subjects with the rs2298599 risk A/A genotype, compared
with G allele carriers, had higher scores of schizotypal traits (F1,178=4.08, p=0.045), particularly the interpersonal factor
(F1,178=5.85, p=0.017).
Discussion: These results suggest that a genetic variation in the p250GAP gene might increase susceptibility not only for
schizophrenia but also for schizotypal personality traits. We concluded that the p250GAP gene might be a new candidate
gene for susceptibility to schizophrenia.
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Introduction
Schizophrenia is a common and complex psychiatric disease.
The lifetime morbidity rate is 0.5–1.0% across distinct popula-
tions. Family, twin and adoption studies of schizophrenia have
indicated that there are strong genetic factors and have estimated
the rate of schizophrenia heritability at 80% [1,2]. Although genes
implicated in the pathogenesis of schizophrenia have been found
using several approaches, such as through association studies of
candidate genes, genome-wide association studies (GWAS), copy
number variation (CNV) studies and pedigree studies [3,4], the
exact genetic factors of this complex disease remain to be
explained.
Hypofunction of the glutamate N-Methyl-d-aspartate (NMDA)
receptor is strongly implicated in the pathophysiology of
schizophrenia. NMDA receptor antagonists, such as phencyclidine
(PCP) and ketamine, mimic symptoms of the disorder in humans
and exacerbate symptoms in patients with schizophrenia [5].
These NMDA receptor antagonists induce schizophrenia-like
symptoms in humans. Preclinically, they have been shown to
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e35696induce similar symptoms and to induce neural circuitry changes
reminiscent of schizophrenia [6]. The ability of these NMDA
receptor antagonists to induce a schizophrenia-like phenotype
supports the concept that schizophrenia may be the result of
reduced or abnormal functioning of NMDA receptors. Altered
NMDA receptor binding density in several brain regions, such as
in the anterior cingulate cortex, has been reported in schizophre-
nia [7,8]. The NR2 subunits of the NMDA receptor are spatially
and developmentally regulated, and they provide an important
level of receptor regulation [9,10]. NR2A and NR2B are the
predominant subunits in the cortex, striatum and hippocampus
[11,12,13]. In particular, these three areas are closely associated
with the pathology of schizophrenia and with the neural circuits
within and between these regions [14]. In patients with
schizophrenia, alterations have been observed in the NR2 subunit
mRNA and protein in the prefrontal cortex, including a reduction
in NR2A mRNA and NR2B protein levels [15,16]. Additionally,
the NR2B subunit mRNA levels were increased in the hippocam-
pus [17]. Therefore, different expression of NR2 subunits could
play an important role in the pathophysiology of schizophrenia.
The NMDA receptor regulates activity-dependent spine mor-
phological plasticity by modulating the actin cytoskeleton [18]. As
the key regulators of actin cytoskeleton dynamics, the Rho family of
GTPases, including RhoA, Cdc42, and Rac1 and their regulators,
play an important role in NMDA receptor-mediated spine
morphogenesis [18,19]. In our previous study, we identified the
p250GAP gene (also known as p200RHOGAP, GRIT, KIAA0712,
RICS,o rARHGAP32: OMIM 608541) as a novel NMDA receptor-
interacting RhoGAP [20,21,22,23]. This gene spans approximately
56.17 kb of the genomic DNA and is located on chromosome
11q24.3. p250GAP is highly enriched in the central nervous system,
is concentrated in the post-synaptic densities in neurons and is co-
localized with the NR2B subunit of the NMDA receptor [20].
Knockdown of p250GAP increased spine width and elevated the
endogenous RhoA activity in primary hippocampal neurons,
suggesting that p250GAP regulates spine morphogenesis through
its RhoGAP activity for RhoA [24]. Importantly, p250GAP activity
and localization within neurons are regulated by NMDA receptor
activity [20,24], suggesting that p250GAP, together with the
NMDA receptor, regulates NMDA receptor-mediated spine
morphogenesis. Given that neuropathological studies of schizo-
phrenia have shown alterations in spine morphology [25,26], we
hypothesized that the p250GAP gene may be related to the
pathophysiology of schizophrenia. In this study, we investigated
the association between the p250GAP gene and schizophrenia in a
Japanese population using a gene-based approach.
Schizotypalpersonalitydisorder(SPD)isoneoftheschizophrenia
spectrumdisordersandischaracterized bysocialavoidance,ideasof
reference, vagueness, magical thinking, odd speech, illusions and
paranoid ideation. The lifetime prevalence of SPD has been
estimated at 3.9% [27], making it one of the more common
psychiatric disorders. The prevalence rate of SPD in relatives of
individuals with schizophrenia (6.9%) was higher than the
prevalence rates found either in relatives of individuals with other
psychiatric disorders or in mentally healthy subjects [28]. Twin
studies have estimated that the heritability of the latent liability to
SPD is 61–72% [29,30]. Premorbid SPD is related to the
development of schizophrenia [31]. These findings suggest that
SPD shares common genetic influences with schizophrenia. The
traits of SPD were incorporated in the SPD criteria in the Diagnostic
and Statistical Manual of Mental Disorders, third edition (DSM-III), and
the traits are listed in the DSM-IV-TR on Axis II. These traits can
be identified using a well-validated questionnaire, such as the
Schizotypal Personality Questionnaire (SPQ) [32]. The heritability
rates of three schizotypal trait factors, cognitive/perceptual,
interpersonal and disorganization, have been estimated at 40 to
60% [33,34]. We recently demonstrated that a genome-wide
genetic variant for schizophrenia in the ZNF804A gene was
associated with schizotypal personality traits [35]. Additionally, we
investigated whether a genetic variant in the p250GAP gene was
associated with schizotypal personality traits in healthy subjects.
Materials and Methods
Ethics statement
Written informed consent was obtained from all subjects after
the procedures had been fully explained. This study was
performed in accordance with the World Medical Association’s
Declaration of Helsinki and approved by the Osaka University
Research Ethics Committee.
Subjects
The subjects of our genetic association study were 431 patients
with schizophrenia (48.7% male (210 males, 221 females), mean
age 6 SD was 49.7615.4 years) and 572 healthy controls (46.7%
male (267 males, 305 females), mean age 6 SD was 61.9620.4
years). The sex ratio did not differ significantly between the groups
(x
2=0.41, p=0.52), but the mean age was significantly different
(z=211.49, p,0.001). The subjects were all biologically unrelated
and were Japanese. The subjects were recruited from both
outpatient and inpatient units at Osaka University Hospital and
other psychiatric hospitals. Each patient with schizophrenia had
been diagnosed by at least two trained psychiatrists by unstruc-
tured clinical interviews, according to the criteria of the DSM-IV.
When the diagnosis of the two trained psychiatrists was discordant,
they discussed the diagnosis. When the diagnostic disputes were
resolved and the patient was diagnosed as schizophrenic, we
included the patient. When the diagnostic disputes were not
resolved by discussion or the patient was not diagnosed as
schizophrenia, we excluded the patient. Controls were recruited
through local advertisements. Psychiatrically healthy controls were
evaluated using unstructured interviews to exclude individuals
with current or past contact with psychiatric services, with
experience with psychiatric medications or who were not
Japanese. We did not assess the controls for their family history
of mental disorders, such as schizophrenia, bipolar disorder, or
major depressive disorder. The ethnicity was determined by self-
report and was not confirmed by genetic analyses.
Data for the schizotypal personality trait analysis were available
for 180 healthy subjects [48.3% male (87/93), mean age 6 SD:
36.5611.5 years]. The subjects were included in the genetic
association analysis. The subjects included in the analysis met
additional criteria. Psychiatrically, medically and neurologically
healthy controls were evaluated using the Structured Clinical
Interview for DSM-IV-Non-Patient Edition (SCID-I/NP) to
exclude individuals who had received psychiatric medications or
who had first- or second-degree relatives with psychiatric
disorders. Additionally, subjects were excluded from this study if
they had neurological or medical conditions that could have
potentially affected their central nervous system, such as atypical
headaches, head trauma with loss of consciousness, chronic lung
disease, kidney disease, chronic hepatic disease, thyroid disease,
active cancer, cerebrovascular disease, epilepsy, seizures, sub-
stance-related disorders or mental retardation.
SNP selection, genotyping and genomic sequencing
This study was designed to examine the association between the
p250GAP gene and schizophrenia by tagging single-nucleotide
Association of p250GAP Gene with Schizophrenia
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regions (65 kb). Of the 31 SNPs in the p250GAP gene and
flanking regions, we selected eight tagging SNPs using the
TAGGER algorithm (Paul de Bakker, http://www.broad.mit.
edu/mpg/tagger) with the criteria of r
2 greater than 0.5 in ‘pair-
wise tagging only’ mode and a minor allele frequency (MAF)
greater than 5%. The selection was implemented in Haploview 4.2
using HapMap data release 24/PhaseII Nov 08, on NCBI B36
assembly, dbSNP b126 (Japanese in Tokyo (JPT), Chr 11:
128,338,052..128,404,222) (Table S1). The eight tagging SNPs
were rs493172, rs10893947, rs2276027, rs3796668, rs581258,
rs3740829, rs546239 and rs2298599. The markers are shown in
Table 1; the orientation and the alleles are reported on the
genomic minus strand. The positions of the eight SNPs analyzed in
the present study and the LD relationships between the SNPs in a
HapMap JPT population are shown in Figure 1. Venous blood
was collected from the subjects. Genomic DNA was extracted
from the whole blood using standard procedures. The SNPs were
genotyped using the TaqMan 59-exonuclease allelic discrimination
assay (Applied Biosystems; Foster City, California, USA) as
previously described [36,37]. Detailed information on the PCR
conditions is available upon request. Genotyping call rates were
99.3% (rs493172), 98.9% (rs10893947), 99.1% (rs2276027),
99.7% (rs3796668), 98.4% (rs581258), 99.2% (rs3740829),
98.5% (rs546239) and 99.3% (rs2298599). No deviations from
the Hardy-Weinberg equilibrium (HWE) in the examined SNPs
were detected (p.0.05). Additionally, with 48 subjects with
schizophrenia, we confirmed a SNP significantly associated with
schizophrenia, genotyped by the TaqMan method, using direct
DNA sequencing. These subjects were included in the genetic
association analysis. The genomic regions were amplified by PCR
using a pair of primers for rs2298599, 59- AAGTCAGCCCA-
GACTCTCCA -39 and 59- GAGGGAGGAAGGGATTTTTG -
39. PCR for each sample was carried out in a total volume of 40 ml
using a Gene AmpH PCR System 9700 (Applied Biosystems, CA,
U.S.A). The PCR cycling conditions were 94uC for 10 minutes, 30
cycles at 94uC for 1 minute, 60uC for one minute and 72uC for
1 minute, followed by an incubation at 72uC for 10 minutes. The
PCR products were purified using a QIA quickH PCR Purification
Kit (QIAGEN, CA, USA), and the purification products were
sequenced using a Big DyeH Terminator v1.1 Cycle Sequencing
Kit (Applied Biosystems, CA, USA). Cycle sequencing conditions
were 96uC for 2 minutes, 25 cycles of 96uC for 20 seconds, 50uC
for 30 seconds and 60uC for 2 minutes, using a Gene AmpH PCR
System 9700. The PCR products from the cycle sequencing were
purified using a Big DyeH XTerminator
TM Purification Kit
(Applied Biosystems, CA, U.S.A.), and they were sequenced using
an ABI PRISMH 3700 DNA Analyzer (Applied Biosystems, CA,
U.S.A.). The sequencing was checked with SEQUENCHER ver.
4.7 (Gene Codes, U.S.A.).
Schizotypal personality trait analysis
To assess schizotypal personality traits, a full Japanese version of
the SPQ was administered to healthy subjects [38,39]. The SPQ is
a 74-item self-report questionnaire with a ‘‘yes/no’’ response
format [40]. All items answered ‘‘yes’’ were scored 1. The SPQ
measures nine subscales of specific schizotypal features, which are
ideas of reference, odd beliefs/magical thinking, unusual percep-
tual experiences, suspiciousness/paranoid ideation, social anxiety,
no close friends, constricted affect, eccentric/odd behavior and
odd speech. The total SPQ score was obtained by summing the
scores from all of the items. The three schizotypal trait factors,
cognitive/perceptual, interpersonal and disorganization, were
derived by summing the related subscale raw scores according to
the three-factor model of Raine and colleagues [32]. Full-scale IQ
was assessed using the Wechsler Adult Intelligence Scale, Revised
or Third edition.
Statistical analysis
Differences in clinical characteristics between the patients and
the controls or between the genotype groups were analyzed using
the x
2 test for categorical variables and the Mann-Whitney U-test
for continuous variables, using the PASW Statistics 18.0 software
(SPSS Japan Inc., Tokyo, Japan). We performed power calcula-
tions using the Power Calculator for Two Stage Association
Studies (http://www.sph.umich.edu/csg/abecasis/CaTS [41]).
The power estimates were based on the allele frequency of 0.35
(rs2298599) in the controls and an alpha level of 0.05. Power was
calculated under a prevalence of 0.01 using a multiplicative model
that assumed varying degrees of the odds ratio (OR). Statistical
analyses for the genetic associations were performed using the
SNPAlyze V5.1.1 Pro software (DYNACOM, Yokohama, Japan).
Deviation from the HWE was tested using x
2 tests for goodness of
Table 1. Genotypic and allelic distributions for SNPs in the p250GAP between patients with schizophrenia and controls.
Marker SCZ (n=431)
CON
(n=572) Genotypic SCZ CON Allelic OR
SNP IDs Position
a M/m gene M/M M/m m/m M/M M/m m/m p (x2) MAF p (x2) (95% CI)
rs493172 128388089 C/G intron1 346 77 3 451 116 3 0.63 (0.9) 0.10 0.11 0.49 (0.5) 0.90 (0.67–1.21)
rs10893947 128375634 G/A intron1 122 217 88 177 294 94 0.25 (2.8) 0.46 0.43 0.14 (2.2) 1.15 (0.96–1.37)
rs2276027 128355514 T/C intron8 241 158 27 303 229 36 0.57 (1.1) 0.25 0.27 0.42 (0.7) 0.92 (0.75–1.13)
rs3796668 128349062 A/C intron11 186 182 62 206 292 72 0.020 (7.8) 0.36 0.38 0.22 (1.5) 0.89 (0.74–1.07)
rs581258 128348083 A/G exon12 293 125 8 373 171 17 0.46 (1.6) 0.17 0.18 0.32 (1.0) 0.89 (0.70–1.12)
rs3740829 128344366 A/G exon13 375 50 2 513 54 1 0.37 (2.0) 0.06 0.05 0.18 (1.8) 1.30 (0.89–1.91)
rs546239 128340968 A/G 39 325 91 9 402 149 12 0.18 (3.4) 0.13 0.15 0.11 (2.6) 0.81 (0.63–1.05)
rs2298599 128340162 G/A 39 167 184 76 219 296 53 0.00015 (17.6) 0.39 0.35 0.07 (3.3) 1.18 (0.99–1.42)
SCZ: patients with schizophrenia, CON: controls, M: major allele, m: minor allele, MAF: minor allele frequency, OR: odds ratio, 95%CI: 95% confidence interval.
adb SNP build 129.
All of the alleles are represented according to the minus strand DNA sequence. Numbers of genotypes were represented as genotype counts. P values,0.05 are in
boldface and underlined.
doi:10.1371/journal.pone.0035696.t001
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phisms between the patients and the controls were analyzed using
x
2 tests.
Pairwise linkage disequilibrium (LD) analyses, expressed by r
2,
were applied to detect the intermarker relationships in each group
using the Haploview 4.2 software (http://www.broad.mit.edu/
mpg/haploview/contact.php). Haplotype frequencies were estimat-
ed using the maximum likelihood method with the genotyping data.
We used the expectation-maximization algorithm from the SNPA-
lyze V5.1.1 Pro software. Rare haplotypes, detected in less than 3%
of the patients and the controls, were excluded from the haplotypic
association analysis, as previously described [42,43]. Using a 262
contingency table approach, we performed 10,000 permutations of
significanceteststo determine empiricalsignificance.Weused a 2- to
8-window fashion analysis. We applied Bonferroni corrections in
allelic and genotypic association analyses (eight tests) and in
haplotypic association analyses (28 independent global tests).
The effects of the p250GAP genotype on the total score and on
the three factors of the SPQ were analyzed by a one-way analysis
of variance (ANOVA). To control confounding factors, the effect
of the p250GAP genotype on the significance factor of the SPQ was
analyzed by a one-way analysis of covariance (ANCOVA). Age,
sex and education years were used as covariates because the SPQ
total score and the three factors were correlated with these
confounding factors in a previous study [44]. Standardized effect
sizes were calculated using Cohen’s d method (http://www.uccs.
edu/faculty/lbecker). All p values are two tailed, and statistical
significance was defined as p,0.05.
Results
Genetic association analysis
Our study size of 431 patients with schizophrenia and 572
controls had sufficient power (.80%) to detect a genetic effect at
ORs of 1.30 or larger when the allele frequency was 0.35. The
genotype and allele frequencies of the eight tagging SNPs located
in the p250GAP gene and flanking regions are summarized in
Table 1. We found significant differences in genotype frequencies
between the patients and the controls in rs3796668 (x
2=7.8,
p=0.020) and rs2298599 (x
2=17.6, p=0.00015). No allelic or
genotypic associations were observed with schizophrenia for any
other SNPs (p.0.05). The major genotype frequency of rs3796668
was significantly higher in the patients with schizophrenia (43%)
than in the controls (36%) (x
2=5.2, p=0.023), but no differences
were observed in the frequencies of the minor or heterozygous
genotypes of rs3796668 (p.0.05). The minor genotype frequency
of rs2298599 was higher in the patients with schizophrenia (18%)
than in the controls (9%) (x
2=15.5, p=0.000083), but no
differences were observed in the frequencies of the major or
heterozygous genotypes of rs2298599 (p.0.05). The evidence for
genotypic association of rs2298599 remained significant after a
Bonferroni correction for multiple tests (corrected p=0.0012).
Genomic sequencing data for rs2298599 for each individual were
in agreement with genotyping data using the TaqMan methods.
Haplotype analysis showed a marginally significant association
with schizophrenia in the rs3740829- rs546239- rs2298599
haplotype (x
2=7.9, global p=0.049) (Table S2). However, the
Figure 1. The genomic structure of p250GAP and linkage disequilibrium of the p250GAP in the HapMap JPT. The genomic structure of
p250GAP is based on an entry in the Entrez Gene database (National Center for Biotechnology Information). The locations of the SNPs analyzed in this
study are indicated by arrows. The numbers indicated in parentheses refer to the numbering of the SNPs in the linkage disequilibrium (LD) diagram.
The distances of the exons-introns and the intermarkers are drawn to scale. The LDs between the pairwise SNPs are shown using the r
2 value at the
bottom of the map of the gene structure for the HapMap JPT samples. High levels of LD are represented by black (r
2) coloring, with increasing color
intensity shown by the color bars.
doi:10.1371/journal.pone.0035696.g001
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after Bonferroni correction).
The LD relationships between the investigated markers are
provided in Figure S1. The LD pattern observed in our controls
was similar to our patients and the JPT HapMap samples;
however, it was different from the LD pattern of the Utah
residents with Northern and Western European ancestry from the
CEPH collection (CEU) HapMap samples.
In silico genotype-expression analysis
We examined an association between the rs2298599 and the
expression levels of the p250GAP gene inimmortalized lymphoblasts
derived from 45 HapMap JPT subjects using WGAViewer software
(http://compute1.lsrc.duke.edu/softwares/WGAViewer). However,
in silico analysis revealed that there was no significant association
between the SNP and the p250GAP expression in the immortalized
lymphoblasts (p=0.28).
Impact of p250GAP genotype on schizotypal personality
traits
We examined a possible association between the p250GAP
genotype of rs2298599 and schizotypal personality traits in healthy
subjects. Compared to controls, patients with schizophrenia were
significantly more likely to carry the rs2298599 A/A genotype.
Therefore, these analyses focused on a comparison of homozygous
risk A/A genotype carriers versus homozygous carriers of one or
two copies of the G allele (a combined G/G and G/A genotype
group), under a recessive inheritance model of the risk A/A
genotype. Demographic variables, age, sex, and full-scale IQ were
not significantly different between the genotype groups, except for
years of education (z=22.05, p=0.041) (Table 2). We first
examined the possible effect of p250GAP rs2298599 on the total
SPQ score and found a significant effect of the genotype
(F1,178=4.08, p=0.045) (Table 3). Then, we investigated the
genotype effects on the three SPQ factors, cognitive/perceptual,
interpersonal and disorganization. A significant genotype effect
was observed on the interpersonal factor (F1,178=5.85, p=0.017),
but no significant genotype effects were observed on the cognitive/
perceptual or disorganization factors (p.0.1). The effect of
genotype on the interpersonal factor remained significant after
adjusting for confounding factors (F1,175=4.71, p=0.031). Sub-
jects with the risk A/A genotype of rs2298599 showed higher
scores on schizotypal traits, particularly the interpersonal factor,
compared with subjects with the G allele (Figure 2). The effect
sizes of the total score and interpersonal factor were 0.41 and 0.47,
respectively. When the two genotypes were divided into opposite
two genotype groups (homozygous carriers of one or two copies of
the A allele versus homozygous G/G genotype carriers) under a
dominant model of inheritance, there was no significant difference
in scores between A carriers and individuals with G/G genotype
(p.0.05, Table S3).
Discussion
This study is the first investigation of the association of the
p250GAP gene with schizophrenia. In this study, we first provided
evidence that a genetic variant of the p250GAP gene was associated
with the risk for schizophrenia. The frequency of individuals with
the rs2298599 risk A/A genotype was higher in patients with
schizophrenia than in the controls. Second, we indicated that the
risk genotype of the p250GAP gene was associated with high
schizotypal personality traits, particularly the interpersonal factor,
in healthy subjects. Individuals with the rs2298599 risk A/A
genotype scored higher on schizotypal personality traits and the
interpersonal factor than did individuals with non-risk genotypes.
These findings suggest that the p250GAP gene may be related to
the risk for schizophrenia and the schizotypal personality traits.
Rs2298599 is situated within the relatively large LD block,
which includes the p250GAP and the P53AIP1 (OMIM 605426)
genes (Figure S2). The SNP is located 2.9 kb downstream of the
p250GAP gene and located 22.1 kb upstream of the P53AIP1 gene.
To confirm whether a significant association signal of rs2298599
with schizophrenia is attributed to the p250GAP gene, we checked
strength of LDs in the genomic region (650 kb) around rs2298599
using HapMap data (JPT, Chr 11: 128,290,162..128,390,161).
Seven SNPs was related to rs2298599 with the criteria of r
2 greater
than 0.8. Of the seven SNPs, five SNPs were located 59 upstream
from rs2298599 and four SNPs were included in the p250GAP
gene. Two SNPs were located 5.2 and 7.9 kb downstream from
rs2298599. These findings suggest that our association signal could
be attributed to the p250GAP but not the P53AIP1 gene. However,
the P53AIP1 may be a susceptibility gene for schizophrenia. Future
Table 2. Demographic variables for subjects included in the
SPQ analysis.
Total G carrier A/A p values (z)
Variables (n=180) (n=159) (n=21)
Age (years) 36.6611.5 36.5611.5 37.5611.8 0.69 0.40
Sex (male/female)
a 87/93 77/82 10/11 0.94 ,0.01
Education (years) 15.462.4 15.662.4 14.462.0 0.041 22.05
Full scale IQ 109.0612.0 109.0612.2 108.8611.2 0.75 20.33
Means 6 SD are shown. P values,0.05 are in boldface and underlined.
ax
2 test.
doi:10.1371/journal.pone.0035696.t002
Table 3. Association of the p250GAP gene risk variant with the schizotypal personality traits.
SPQ Total G carrier A/A Genotype effect
Variables (n=180) (n=159) (n=21) Cohen’s dF 1,178 p values g
2
Total score 10.768.9 10.368.4 14.4611.4 20.41 4.08 0.045 0.02
Cognitive/perceptual 3.363.8 3.263.7 4.064.5 20.19 0.94 0.33 0.01
Interpersonal 5.064.5 4.764.1 7.266.3 20.47 5.85 0.017 0.03
Disorganization 3.163.3 3.063.3 4.163.8 20.31 2.13 0.15 0.01
SPQ: Schizotypal Personality Questionnaire. Means 6 SD are shown. The effect sizes are typically categorized as small (d=0.20, g
2=0.01), medium (d=0.50, g
2=0.06) or
large (d=0.80, g
2=0.14). Significant p values are shown in boldface and underlined.
doi:10.1371/journal.pone.0035696.t003
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P53AIP1 and schizophrenia.
Although significant associations between the p250GAP gene
and schizophrenia were observed in this study, no experimental
evidence has indicated that the rs2298599 SNP of p250GAP is
functional. To define a possibly functional SNP associated with the
disease, followed by evaluation of altered function caused by the
relevant SNP, may be able to narrow down the region of the
association observed with the rs2298599. For example, gene
expression analyses at either mRNA or protein levels of the
p250GAP gene using postmortem or lymphoblast samples may be
an alternative approach. We examined an association between the
rs2298599 and p250GAP expression in immortalized lymphoblasts.
However, in silico analysis revealed that the SNP might not be
related to p250GAP mRNA expression in a Japanese population. A
future biological study of the function of rs2298599 or p250GAP
gene is required to verify our results.
MicroRNAs (miRs) regulate cellular fate by controlling the
stability or translation of the mRNA transcripts. The miR132,
located on 17p12.3, controls p250GAP protein levels and regulates
neuronal morphogenesis by decreasing the levels of p250GAP
[45]. The miR132 target sequence in the p250GAP 39UTR,
AACAGTCCACTGTCCAGCAGAGG, is conserved across ver-
tebrate evolution. We performed a mutation search of the genomic
region (the target sequence of miR1326250 bp) in the p250GAP
gene using 48 patients with schizophrenia to evaluate the presence
of a genetic variant in this region. However, we had no
polymorphisms in our sequence data. This result suggests that
the miR132 target sequence in the p250GAP might not play a
major role in risk for schizophrenia.
Several molecular genetic studies have investigated the influences
of susceptibility genes for schizophrenia on schizotypal personality
traits. These studies have reported associations between the COMT
[46,47,48], NRG1 [49], DTNBP1 [50,51], RGS4 [52], DAAO [51]
and ZNF804A [35] genes and schizotypal components. Risk alleles
or haplotypes of schizophrenia were correlated with high scores on
schizotypal personality traits. Of these genes, the COMT, NRG1,
DTNBP1, DAAO and RGS4 genes, as well as the p250GAP gene, are
directly or indirectly responsible for NMDA receptor-mediated
glutamate transmission or signaling via glutamate receptors [53].
However, involvement of the glutamate NMDA receptors in SPD is
still unknown. Further research will need to clarify the relationship
between the glutamate NMDA receptors and SPD.
The interpretation of our results has several limitations. We
found a significant association of the p250GAP gene with
schizophrenia using 431 patients with schizophrenia and 572
controls. Our sample sizes had sufficient power (.0.80) to detect
the effects of ORs of 1.30 or larger. Because our results were based
on a relatively small sample to detect the effects of ORs of 1.30 or
fewer, a future replication study using larger sample sizes is needed
to confirm our findings. Our positive results might have been
derived from a sample bias due to population stratification and
non-age-matched samples, although the Japanese are a relatively
homogeneous population. We used schizotypal personality traits as
a phenotype of interest. As the assessment of the personality traits
was based on a self-reported questionnaire, it was not an objective
measurement. Importantly, to be included in the SPQ analysis,
subjects were not required to meet criteria for SPD. We had
hypothesized that schizotypal personality trait is a continuous
measure of the genetic liability to schizophrenia. G allele carriers
had marginally higher years of education and lower scores on
schizotypal traits than did subjects with the risk A/A genotype. In
a previous study, years of education had significant inverse effects
on the total SPQ score and the three factor scores, indicating that
the SPQ scores decreased with increased years of education [44].
The educational level difference between the genotype groups may
have affected the genotype effects on the schizotypal personality
trait. However, our results remained significant after adjusting for
years of education.
In this study, we proposed p250GAP as a new candidate gene for
susceptibility to schizophrenia. The association between the
p250GAP gene and schizophrenia might partially explain the
relationship between the hypofunction of the glutamate NMDA
receptor and schizophrenia. Future studies are required to confirm
the association between the p250GAP gene and schizophrenia in
other populations.
Supporting Information
Figure S1 Linkage disequilibrium pattern of eight SNPs
in the patient, control, HapMap JPT and CEU groups. The
linkage disequilibriums (LDs) between the pairwise SNPs are shown
using the r
2 value separately for the patients with schizophrenia, the
controls, the HapMap JPT samples and the HapMap CEU samples.
High levels of LD (r
2) are represented by black coloring, and
increasing color intensity from 0 to 100 is shown by the color bars.
The numbers (from 1 to 8) in the boxes refer to the eight tagging
SNPs; rs493172 (1), rs10893947 (2), rs2276027 (3), rs3796668 (4),
rs581258 (5), rs3740829 (6), rs546239 (7) and rs2298599 (8).
(TIF)
Figure S2 Linkage disequilibrium in the genomic region
(±50 kb) around rs2298599 SNP in HapMap JPT. LD
structure is based on an entry in the HapMap data release 24/
PhaseII Nov 08, on NCBI B36 assembly, dbSNP b126 (JPT, Chr
11: 128,290,162..128,390,161). The LD structure between the
pairwise SNPs is shown using the r
2 value. High levels of LD are
represented by black (r
2) coloring, with increasing color intensity.
(TIF)
Figure 2. The association between the risk-associated p250GAP
genotype and SPQ total score and the three factors. The gray
bars represent individuals who are G-carriers (G/G and G/A genotypes)
of rs2298599. The white bars represent individuals with the A/A
genotype of the SNP. Error bars represent standard errors of the mean. *
p,0.05.
doi:10.1371/journal.pone.0035696.g002
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